Damora Therapeutics, Inc. (DMRA) income statement
DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$22.98+0.42 (+1.86%)
Close on Nov 18, 2026Market cap $1.42BP/E 5.8Yield 0.00%
Damora Therapeutics, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -165.5%
Financial strength
- Current ratio
- 14.80
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 974.2%
Valuation
- P/E ratio
- 5.8
- Price to sales
- –
- Price to book
- 2.87
- Dividend yield
- 0.00%
See a number that looks wrong?